First US FDA approval of CAR-T therapy hikes expectations for Korean biotech ventures - (The Korea Herald via NewsPoints Desk)

  • The approval of Novartis' CAR-T therapy Kymriah has boosted expectations for South Korean biotech ventures developing similar treatments, The Korea Herald reported Sunday.

  • The approval has also heightened expectations for companies such as Gilead Sciences, which recently purchased Kite Pharma.

  • Regarding Korean firms, ViroMed, AbClon and Green Cross Cell are all developing CAR-T therapies, although all are in the early stages of development.

  • ViroMed licenced its CAR-T technology to bluebird bio in 2015.

  • AbClon claims its CAR-T platform minimises the onset of cytokine release syndrome, while Green Cross Cell is developing therapies targeting solid tumours.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.